Characterizing Pharmacogenetic Testing Among Children’s Hospitals

Although pharmacogenetic testing is becoming increasingly common across medical subspecialties, a broad range of utilization and implementation exists across pediatric centers. Large pediatric institutions that routinely use pharmacogenetics in their patient care have published their practices and e...

Full description

Bibliographic Details
Main Authors: Jacob T. Brown, Laura B. Ramsey, Sara L. Van Driest, Ida Aka, Susan I. Colace
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.12931
id doaj-c8b2cc9e26bc49a8bd6ad877ef14041e
record_format Article
spelling doaj-c8b2cc9e26bc49a8bd6ad877ef14041e2021-03-25T15:37:46ZengWileyClinical and Translational Science1752-80541752-80622021-03-0114269270110.1111/cts.12931Characterizing Pharmacogenetic Testing Among Children’s HospitalsJacob T. Brown0Laura B. Ramsey1Sara L. Van Driest2Ida Aka3Susan I. Colace4Department of Pharmacy Practice and Pharmaceutical Sciences College of Pharmacy University of Minnesota Duluth Duluth Minnesota USADepartment of Pediatrics University of Cincinnati College of Medicine Cincinnati Ohio USADepartment of Pediatrics Vanderbilt University Medical Center Nashville Tennessee USADepartment of Pediatrics Vanderbilt University Medical Center Nashville Tennessee USADepartment of Pediatrics Nationwide Children’s Hospital Columbus Ohio USAAlthough pharmacogenetic testing is becoming increasingly common across medical subspecialties, a broad range of utilization and implementation exists across pediatric centers. Large pediatric institutions that routinely use pharmacogenetics in their patient care have published their practices and experiences; however, minimal data exist regarding the full spectrum of pharmacogenetic implementation among children’s hospitals. The primary objective of this nationwide survey was to characterize the availability, concerns, and barriers to pharmacogenetic testing in children’s hospitals in the Children’s Hospital Association. Initial responses identifying a contact person were received from 18 institutions. Of those 18 institutions, 14 responses (11 complete and 3 partial) to a more detailed survey regarding pharmacogenetic practices were received. The majority of respondents were from urban institutions (72%) and held a Doctor of Pharmacy degree (67%). Among all respondents, the three primary barriers to implementing pharmacogenetic testing identified were test reimbursement, test cost, and money. Conversely, the three least concerning barriers were potential for genetic discrimination, sharing results with family members, and availability of tests in certified laboratories. Low‐use sites rated several barriers significantly higher than the high‐use sites, including knowledge of pharmacogenetics (P = 0.03), pharmacogenetic interpretations (P = 0.04), and pharmacogenetic‐based changes to therapy (P = 0.03). In spite of decreasing costs of pharmacogenetic testing, financial barriers are one of the main barriers perceived by pediatric institutions attempting clinical implementation. Low‐use sites may also benefit from education/outreach in order to reduce perceived barriers to implementation.https://doi.org/10.1111/cts.12931
collection DOAJ
language English
format Article
sources DOAJ
author Jacob T. Brown
Laura B. Ramsey
Sara L. Van Driest
Ida Aka
Susan I. Colace
spellingShingle Jacob T. Brown
Laura B. Ramsey
Sara L. Van Driest
Ida Aka
Susan I. Colace
Characterizing Pharmacogenetic Testing Among Children’s Hospitals
Clinical and Translational Science
author_facet Jacob T. Brown
Laura B. Ramsey
Sara L. Van Driest
Ida Aka
Susan I. Colace
author_sort Jacob T. Brown
title Characterizing Pharmacogenetic Testing Among Children’s Hospitals
title_short Characterizing Pharmacogenetic Testing Among Children’s Hospitals
title_full Characterizing Pharmacogenetic Testing Among Children’s Hospitals
title_fullStr Characterizing Pharmacogenetic Testing Among Children’s Hospitals
title_full_unstemmed Characterizing Pharmacogenetic Testing Among Children’s Hospitals
title_sort characterizing pharmacogenetic testing among children’s hospitals
publisher Wiley
series Clinical and Translational Science
issn 1752-8054
1752-8062
publishDate 2021-03-01
description Although pharmacogenetic testing is becoming increasingly common across medical subspecialties, a broad range of utilization and implementation exists across pediatric centers. Large pediatric institutions that routinely use pharmacogenetics in their patient care have published their practices and experiences; however, minimal data exist regarding the full spectrum of pharmacogenetic implementation among children’s hospitals. The primary objective of this nationwide survey was to characterize the availability, concerns, and barriers to pharmacogenetic testing in children’s hospitals in the Children’s Hospital Association. Initial responses identifying a contact person were received from 18 institutions. Of those 18 institutions, 14 responses (11 complete and 3 partial) to a more detailed survey regarding pharmacogenetic practices were received. The majority of respondents were from urban institutions (72%) and held a Doctor of Pharmacy degree (67%). Among all respondents, the three primary barriers to implementing pharmacogenetic testing identified were test reimbursement, test cost, and money. Conversely, the three least concerning barriers were potential for genetic discrimination, sharing results with family members, and availability of tests in certified laboratories. Low‐use sites rated several barriers significantly higher than the high‐use sites, including knowledge of pharmacogenetics (P = 0.03), pharmacogenetic interpretations (P = 0.04), and pharmacogenetic‐based changes to therapy (P = 0.03). In spite of decreasing costs of pharmacogenetic testing, financial barriers are one of the main barriers perceived by pediatric institutions attempting clinical implementation. Low‐use sites may also benefit from education/outreach in order to reduce perceived barriers to implementation.
url https://doi.org/10.1111/cts.12931
work_keys_str_mv AT jacobtbrown characterizingpharmacogenetictestingamongchildrenshospitals
AT laurabramsey characterizingpharmacogenetictestingamongchildrenshospitals
AT saralvandriest characterizingpharmacogenetictestingamongchildrenshospitals
AT idaaka characterizingpharmacogenetictestingamongchildrenshospitals
AT susanicolace characterizingpharmacogenetictestingamongchildrenshospitals
_version_ 1724203454430183424